Clobetasone 0.05% ointment

Objective The objective of this study was to evaluate the effect of postoperative medicated mastoid cavity packing on healing outcomes following canal wall down (CWD) mastoidectomy compared to no packing. Methods This prospective observational study included 125 patients undergoing CWD mastoidectomy, matched for age and sex, and assigned to two groups. Group A (n=62) received medicated mastoid cavity packing containing ofloxacin, ornidazole, clobetasone propionate, and itraconazole on postoperative days 0, 10, and 20. Group B (n=63) received no postoperative packing. Healing outcomes were evaluated and compared between the groups on postoperative days 45, 75, and 105. A p-value of <0.05 was considered statistically significant. Results The groups were comparable in age and sex distribution. The packed group demonstrated significantly higher rates of complete epithelialization on day 45 (48.4% vs. 15.9%, p < 0.0001) and day 75 (72.6% vs. 49.2%, p = 0.007), with no difference observed by day 105. Graft uptake duration was similar between groups (76.94 days in Group A and 76.19 days in Group B). Granulation tissue, mucosal folds, and otorrhea were more frequent in the non-packed group (25.4%, 6.3%, and 4.8% vs 12.9%, 3.2%, and 3.2%, respectively) during early follow-up, though not statistically significant. Mean epithelialization time was significantly shorter in the packed group (84.0 vs. 92.8 days, p = 0.001). Conclusion Medicated mastoid cavity packing promotes earlier epithelialization following CWD mastoidectomy and is associated with a lower incidence of granulation tissue without affecting graft uptake. It offers particular benefits in low-resource settings by enhancing healing and reducing follow-up needs. Larger studies are warranted to establish standardized postoperative care protocols.

Abstract licence: CC BY

Background: Nodule is an inflammatory lesion common in scabies, treating nodular scabies is a challenge. We conducted this study to evaluate the results of treating nodular scabies with Clobetasone butyrate 0.05% in children at the National Dermatology Hospital. Material and methods: Randomized controlled clinical trial study on 100 patients diagnosed with scabies at the age of 2 - 15 years at the National Dermatology Hospital. The study group used Clobetasone butyrate 0.05% with Desloratidine, the control group used Cetaphil Moisturizing with Desloratidine, evaluating the treatment effect after two weeks. Results: The number of nodular lesions in the study group before treatment was 8.72 ± 8.93 and after treatment decreased to 4.2 ± 3.5. In the control group, the number of nodules before treatment was 9.8 ± 9, and after treatment reduced to 6.7 ± 6.5. After two weeks of treatment, the number of nodules decreased with statistical significance in the study group. Treatment response in the study group showed good, average, fair and poor results of 12%, 66%, 22%, 0% respectively; while the control group was 0%, 4%, 46%, 50%; The difference is statistically significant in the two groups. Itching symptom in the study group improved better than the control group. No side effects were recorded in either group. Conclusion: Treatment of nodular scabies with Clobetasone butyrate 0.05% in children reduced the number of lesions, itching symptoms after two weeks and had not recorded any side effects. Key words: Scabies, nodular scabies, Clobetasone butyrate

Abstract licence: CC BY-NC-ND 4.0

Background Tapinarof 1% cream, a non-steroidal topical aryl hydrocarbon receptor (AhR) agonist, has demonstrated effectiveness in the treatment of psoriasis. However, real-world data from low-resource settings is scarce. This study evaluated the real-world effectiveness and safety of tapinarof 1% cream in adults with mild to moderate plaque psoriasis, and it explored differences in outcomes between tapinarof monotherapy and tapinarof combined with a moderately potent topical corticosteroid (clobetasone butyrate). Between-group comparisons were prespecified as exploratory and associative due to non-random allocation. Methods In this prospective observational study, 122 patients with confirmed plaque psoriasis received tapinarof monotherapy (n = 72) or combination therapy with topical corticosteroids (n = 50). Disease severity was assessed using the Psoriasis Area and Severity Index (PASI) and Physician Global Assessment (PGA) at baseline and at weeks 4, 8, and 12. PASI75 and PASI90 responses were analyzed using odds ratios (ORs) and 95% confidence intervals (CIs). Multivariable-adjusted and longitudinal sensitivity analyses were performed. Adverse events (AEs) were recorded. Results At week 12, mean PASI decreased from 6.02 ± 2.40 to 2.78 ± 1.28 in the monotherapy group (p = 0.045) and from 6.46 ± 2.06 to 1.38 ± 1.14 in the combination group (p < 0.001), with a significant between-group difference (p < 0.001). PASI75 was achieved by 30 (60.0%) patients in the combination group and 10 (13.9%) in the monotherapy group (OR = 6.25, 95% CI: 2.38-16.67; p < 0.001). PASI90 responses occurred in 14 (28.0%) and six (8.3%) patients, respectively (OR = 4.35, 95% CI: 1.52-12.50; p = 0.043). Mean changes in PGA differed between groups (p = 0.038). AEs were mild and similar across groups. Conclusion Combination therapy was associated with greater clinical improvement than tapinarof monotherapy in this observational cohort; however, these findings represent associations rather than causal effects, and the incremental contribution of tapinarof cannot be isolated because the combination arm included topical corticosteroids. Randomized studies are required to confirm comparative effectiveness.

Abstract licence: CC BY

A 28-year-old woman presented with a 4-day history of a sudden-onset painful rash on both arms, diarrhea, and a hoarse voice after recent travel to Senegal and the Gambia. The symptoms started on the second day of her trip to the Gambia. There was no relevant past medical history. On examination, there were multiple erythematous and hyperpigmented patches with mild peripheral scaling on the right upper limb, the medial aspect of the left arm, and the left breast. The rest of the physical examination was normal. Photographs of early lesions showed central desquamation. The distribution of the lesions on the distal right arm and proximal right forearm (Figure 1A) and those on the left arm and breast (Figure 1B) exhibited the characteristics of “kissing lesions.” These are discrete, well-defined lesions occurring in mirror-image locations on opposing skin surfaces. 1 This is consistent with a diagnosis of paederus dermatitis, likely acquired in the Gambia. 2 The rash was treated with clobetasone butyrate 0.05% cream twice daily and emollients. The diarrhea and hoarse voice resolved spontaneously. Salmonella DNA was detected in the stool. A respiratory viral swab result was negative, and HIV and syphilis serology results were also negative. Paederus dermatitis is an acute irritant dermatitis caused by contact with the hemolymph of rove beetles ( Paederus sp), which contain a vesicant toxin called pederin. 3 Direct skin contact is not necessary; lesions often appear in areas where the beetle has been crushed or moved. Paederus species are widely distributed, and outbreaks have

Abstract licence: CC BY